Search

Your search keyword '"González-Rivero AF"' showing total 80 results

Search Constraints

Start Over You searched for: Author "González-Rivero AF" Remove constraint Author: "González-Rivero AF"
80 results on '"González-Rivero AF"'

Search Results

1. Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients With Rheumatoid Arthritis.

2. Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis.

3. Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.

4. The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis.

5. Relationship of Hematological Profiles with the Serum Complement System in Patients with Systemic Lupus Erythematosus.

6. The complement system is linked to insulin resistance in patients with systemic lupus erythematosus.

7. Parthanatos type programmed cell death and septic patient mortality.

9. HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus.

10. Relationship of Fibroblast Growth Factor 23 Serum Levels with Disease Characteristics in Systemic Lupus Erythematosus Patients.

11. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus.

12. Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus.

13. Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations.

14. Elevated soluble fas blood concentrations in patients dying from spontaneous intracerebral hemorrhage.

15. Association between blood caspase-9 concentrations and septic patient prognosis.

16. Association between septic patient mortality and blood survivin concentrations.

17. Serum Fas levels during first week of sepsis are associated with severity and mortality.

18. Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients.

19. Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients.

20. Blood soluble Fas concentrations and ischemic stroke patient mortality.

21. High blood Fas concentrations in non-survivor patients with traumatic brain injury.

22. High mortality rate of septic patients with high blood granzyme B concentrations.

23. Amylin serum levels are upregulated in patients with systemic lupus erythematosus.

24. DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation.

25. Association between blood caspase-8 levels and mortality of patients with malignant middle cerebral artery infarction.

26. Association between neutrophil-to-lymphocyte ratio in the first seven days of sepsis and mortality.

27. Blood Bcl-2 levels to predict the mortality of septic patients.

28. Mortality prediction of septic patients by blood caspase-8 levels.

29. Mortality prediction of patients with spontaneous intracerebral hemorrhage by serum soluble Fas ligand concentrations.

30. Association between serum concentrations of anti-apoptotic B-cell lymphoma-2 protein and traumatic brain injury mortality.

31. Blood caspase-8 concentrations and mortality among septic patients.

32. Association of serum soluble Fas concentrations and mortality of septic patients.

33. Mortality of spontaneous intracerebral haemorrhage patients and high serum caspase-8 concentrations.

34. Low blood caspase-8 levels in survivor patients of traumatic brain injury.

35. Serum tissue inhibitor of MMP-1 levels at any moment of the first week of spontaneous intracerebral hemorrhage may predict early mortality.

36. Serum B cell lymphoma-2 concentrations and mortality of patients with spontaneous intracerebral hemorrhage.

37. Beta-cell function is disrupted in patients with systemic lupus erythematosus.

38. Circulating Bcl-2 concentrations and septic patient mortality.

39. High Serum Soluble Fas Ligand Levels in Non-survivor Traumatic Brain Injury Patients.

40. Blood concentrations of proapoptotic sFas and antiapoptotic Bcl2 and COVID-19 patient mortality.

42. Red blood cell distribution width as mortality biomarker in patients with traumatic brain injury.

43. DNA and RNA Oxidative Damage and Mortality of Patients With COVID-19.

44. Serum Levels of B-cell Lymphoma-2 Anti-Apoptotic Protein and Malignant Middle Cerebral Artery Infarction Mortality.

45. Association between blood caspase-8 levels and mortality of patients with malignant middle cerebral artery infarction.

46. Serum caspase-3 levels during the first week of traumatic brain injury.

47. High serum levels of TAC and early mortality in patients with spontaneous intracerebral haemorrhage.

48. Association between red blood cell distribution width and mortality of COVID-19 patients.

49. High Serum Levels of Caspase-3 and Early Mortality in Patients with Severe Spontaneous Intracerebral Hemorrhage.

50. Association between serum sFasL concentrations and sepsis mortality.

Catalog

Books, media, physical & digital resources